Statement Of Comprehensive Income [Abstract]

OSE Immunotherapeutics - Filing #5980970

Concept	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31
Statement of comprehensive income [abstract]
Profit (loss)	—	37 445 EUR	—	—	—	37 445 EUR	—	23 003 EUR	—	—	23 003 EUR	—
Other comprehensive income [abstract]
Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract]
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	—	15,000 EUR	—	—	15,000 EUR	—	—	77,000 EUR	—	—	—	77,000 EUR
Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]
Exchange differences on translation [abstract]
Other comprehensive income, net of tax, exchange differences on translation of foreign operations	—	35,000 EUR	—	—	—	35,000 EUR	—	9,000 EUR	—	—	9,000 EUR	—
Other comprehensive income	—	20,000 EUR	—	—	—	—	—	86,000 EUR	—	—	—	—
Comprehensive income	- EUR	37 425 EUR	- EUR	- EUR	15,000 EUR	37 410 EUR	- EUR	23 089 EUR	- EUR	- EUR	23 012 EUR	77,000 EUR